Hims & Hers Health (NYSE:HIMS) shares exploded 33% at 8:10 am in the premarket trading today after announcing a major expansion of its telehealth weight-loss offerings through a new direct partnership with Novo Nordisk's (NYSE:NVO) NovoCare Pharmacy. Patients can now access authentic, FDA-approved Wegovy through Hims & Hers, LifeMD, and Ro, using a streamlined self-pay model priced at $499 per month. With supply fully restored, the move positions Hims & Hers to capitalize on soaring demand as weight-loss treatments reshape the healthcare landscape.
Wegovy, first approved in 2021, has rapidly become a game-changer for chronic weight management, offering the first weekly GLP-1 therapy for obesity. Its value grew even stronger in 2024 when the FDA expanded its label to cover cardiovascular risk reduction, helping it reach nearly 1.5 million patients across the U.S. By tapping into Novo Nordisk's direct distribution model, Hims & Hers is not only expanding its footprint in one of the fastest-growing markets but also reinforcing its brand as a trusted gateway to premium, FDA-approved treatments.
As more than 100 million Americans live with obesity, Hims & Hers is aggressively positioning itself at the intersection of telehealth and chronic disease management. This partnership enables faster access, direct-to-doorstep delivery, and lower costs for patients all while strengthening Hims & Hers' reputation as a major player in the healthcare space. With today's move, the company is stepping into a higher-growth lane just as traditional healthcare delivery struggles to keep pace with evolving patient expectations.
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。